ReviewJournal of clinical medicine2024

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes.

Kyriakos Dimitriadis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.